Authors
Loading...
High ENO1 expression correlates with poor AML outcomes, suggesting SCD1 inhibition may enhance daunorubicin effectiveness.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: